Abstract:Abstract Background Atrial fibrillation (AF) is prevalent in patients with type 2 diabetes mellitus (T2DM). Glycemic variability (GV) is associated with risk of micro- and macrovascular diseases. However, whether the GV can increase the risk of AF remains unknown. Methods The cohort study used a database from National Taiwan University Hospital, a tertiary medical center in Taiwan. Between 2014 and 2019, a total of 27,246 adult patients with T2DM were enrolled for analysis. Each individual was assessed to determine the coefficients of variability of fasting glucose (FGCV) and HbA1c variability score (HVS). The GV parameters were categorized into quartiles. Multivariate Cox regression models were employed to estimate the relationship between the GV parameters and the risk of AF, transient ischemic accident (TIA)/ischemic stroke and mortality in patients with T2DM. Results The incidence rates of AF and TIA/ischemic stroke were 21.31 and 13.71 per 1000 person-year respectively. The medium follow-up period was 70.7 months. In Cox regression model with full adjustment, the highest quartile of FGCV was not associated with increased risk of AF [Hazard ratio (HR): 1.12, 95% confidence interval (CI) 0.96–1.29, p = 0.148] or TIA/ischemic stroke (HR: 1.04, 95% CI 0.83–1.31, p = 0.736), but was associated with increased risk of total mortality (HR: 1.33, 95% CI 1.12–1.58, p < 0.001) and non-cardiac mortality (HR: 1.41, 95% CI 1.15–1.71, p < 0.001). The highest HVS was significantly associated with increased risk of AF (HR: 1.29, 95% CI 1.12–1.50, p < 0.001), total mortality (HR: 2.43, 95% CI 2.03–2.90, p < 0.001), cardiac mortality (HR: 1.50, 95% CI 1.06–2.14, p = 0.024) and non-cardiac mortality (HR: 2.80, 95% CI 2.28–3.44, p < 0.001) but was not associated with TIA/ischemic stroke (HR: 0.98, 95% CI 0.78–1.23, p = 0.846). The Kaplan–Meier analysis showed significantly higher risk of AF, cardiac and non-cardiac mortality according to the magnitude of GV (log-rank test, p < 0.001). Conclusions Our data demonstrate that high GV is independently associated with the development of new-onset AF in patients with T2DM. The benefit of maintaining stable glycemic levels to improve clinical outcomes warrants further studies.

Glycemic Variability Evaluated by Continuous Glucose Monitoring System is Associated with the 10-Y Cardiovascular Risk of Diabetic Patients with Well-Controlled HbA1c.

Association of Visit-to-Visit Variability of Blood Pressure with Cardiovascular Disease among Type 2 Diabetes Mellitus Patients: A Cohort Study

Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus

Impact of short-term glycemic variability on risk of all-cause mortality in type 2 diabetes patients with well-controlled glucose profile by continuous glucose monitoring: A prospective cohort study

Glycemic variability evaluated by HbA1c rather than fasting plasma glucose is associated with adverse cardiovascular events

Association of Various Glycemic Variability Indices and Vascular Outcomes in Type-2 Diabetes Patients

Glycemic Variability Modifies the Relationship Between Time in Range and Hemoglobin A1c Estimated from Continuous Glucose Monitoring: A Preliminary Study

Glycemic variability assessed using continuous glucose monitoring in individuals without diabetes and associations with cardiometabolic risk markers: A systematic review and meta-analysis

Glycemic Variability Assessed by Continuous Glucose Monitoring and the Risk of Diabetic Retinopathy in Latent Autoimmune Diabetes of the Adult and Type 2 Diabetes

[Impact of Glycemic Variability on Cardiovascular Risk in Diabetes]

Association of long-term visit-to-visit glycemic variability with risk of adverse clinical outcomes in diabetic patients with heart failure with preserved ejection fraction

Relationship between long-term blood glucose variability and major adverse cardiovascular events in patients with acute coronary syndrome

Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus

Research progress on the association between glycemic variability index derived from CGM and cardiovascular disease complications

Glycemic Variability is an Important Risk Factor for Cardiovascular Autonomic Neuropathy in Newly Diagnosed Type 2 Diabetic Patients.

Effects of Intensive Glycemic Control on Microvascular Outcomes in Type 2 Diabetes Mellitus Are Modified by Long-Term HbA1c Variability: A Post Hoc Analysis of the ACCORD Trial

Glycemic variability: Measurement, target, impact on complications of diabetes and does it really matter?

Diabetic peripheral neuropathy and glycemic variability assessed by continuous glucose monitoring: A systematic review and meta-analysis

Glycemic variability: adverse clinical outcomes and how to improve it?

Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus

Effects of intensive glycemic control on microvascular outcomes in type 2 diabetes mellitus are modified by long-term HbA 1c variability: A post hoc analysis of the ACCORD trial